UnitedHealth’s important earnings report will test its resilience

UnitedHealth Group is gearing up to present its financial results for the fourth quarter and full year of 2025, along with guidance for 2026. The announcement is set for tomorrow before the market opens, bringing with it a crucial moment for the healthcare company. Investors are watching closely after a decline of approximately 35% in the share price over the last year, anticipating signs of stabilization or preparing for potential challenges.

Despite facing cost pressures and regulatory scrutiny, major institutional investors have shown confidence in UnitedHealth Group by either maintaining or increasing their stakes in the company. Aegon Asset Management UK, for instance, raised its position by 58.3% and now holds 86,135 shares valued at around $29.74 million. Other significant holders, including Norges Bank, Berkshire Hathaway, and Dodge & Cox, also continue to have substantial interests. Together, institutional investors account for about 87.9% ownership of the company, reflecting a strong belief in UnitedHealth Group’s long-term prospects despite the current environment.

The upcoming report is expected to focus on three key indicators that could influence the market’s reaction:

1. 2026 EPS Forecast: Analysts anticipate guidance of at least $17.25 per share, exceeding the estimated $16.25 for 2025.
2. Operating Margin: A range of 4% to 5% would signal stability in operations.
3. Medical Care Ratio (MCR): This metric, which measures medical costs, has faced significant pressure in 2025.

Analysts predict earnings per share (EPS) for the fourth quarter to be between $2.09 and $2.12. This marks a considerable decline of approximately 69% from the adjusted EPS of $6.81 in the same quarter of the previous year. The interplay between profitability, margins, and future cost metrics will reveal whether UnitedHealth Group is successfully managing its cost structure.

In a strategic move, CEO Stephen Hemsley announced that UnitedHealth Group will return profits from its Affordable Care Act (ACA) insurance business to customers in 2026, foregoing related earnings. Analysts view this decision as a potentially impactful move that could put pressure on competitors more reliant on ACA revenue, such as Centene, Molina Healthcare, and Oscar Health, especially if regulatory frameworks tighten.

Wall Street analysts maintain a “Moderate Buy” rating on UnitedHealth Group with an average price target of $394.91, indicating a potential upside of roughly 17% from the current trading level around $356. Recent adjustments from research firms include Mizuho reiterating a Buy rating with a $430 target, Morgan Stanley slightly lowering its target to $409 while maintaining an Overweight stance, Barclays raising its target to $391 with an Overweight rating, and JPMorgan increasing its target price to $425 and an Overweight rating.

The ongoing regulatory and political pressures add complexity to UnitedHealth Group’s business landscape, as recent testimonies before the U.S. House Energy and Commerce Committee highlight the potential impact of policy decisions on the company’s operations. Currently trading around $356, UnitedHealth Group’s stock has recovered significantly from its 52-week low but remains below its high by about 41%. Key moving averages and valuation metrics provide additional context for investors assessing the company’s future prospects.

Ultimately, tomorrow’s earnings release and guidance will serve as a critical test for UnitedHealth Group, signaling its ability to overcome challenges and drive sustained growth in the evolving healthcare industry.